Intrinsic LifeSciences Revenue and Competitors
Estimated Revenue & Valuation
- Intrinsic LifeSciences's estimated annual revenue is currently $1.1M per year.
- Intrinsic LifeSciences's estimated revenue per employee is $155,000
Employee Data
- Intrinsic LifeSciences has 7 Employees.
- Intrinsic LifeSciences grew their employee count by -30% last year.
Intrinsic LifeSciences's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | President & CEO | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | VP/COO | Reveal Email/Phone |
6 | Controller | Reveal Email/Phone |
Intrinsic LifeSciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Intrinsic LifeSciences?
Intrinsic LifeSciences LLC provides superior, innovative & patent-protected research test kits and certified diagnostics & clinical research CLIA services for hepcidin and erythroferrone (ERFE), the key indicators of anemia, inflammation and pregnancy disorders. Our CAP accredited clinical lab, IntrinsicDxâ„¢, offers the Intrinsic Hepcidin IDxâ„¢ Test service. We also provide RUO immunoassay testing for other related biomarkers. To learn more visit www.intrinsicdx.com, www.intrinsiclifesciences.com.
keywords:N/AN/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
-30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.1M | 7 | 17% | N/A |
#2 | $0.5M | 7 | -12% | N/A |
#3 | $1.1M | 7 | -42% | N/A |
#4 | $0.6M | 7 | N/A | N/A |
#5 | $0.6M | 7 | 17% | N/A |